ClinVar Miner

Submissions for variant NM_012203.2(GRHPR):c.139C>T (p.Arg47Ter)

gnomAD frequency: 0.00007  dbSNP: rs774654020
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001042856 SCV001206563 pathogenic not provided 2024-01-18 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg47*) in the GRHPR gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GRHPR are known to be pathogenic (PMID: 25644115). This variant is present in population databases (rs774654020, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with GRHPR-related conditions. ClinVar contains an entry for this variant (Variation ID: 632541). For these reasons, this variant has been classified as Pathogenic.
PreventionGenetics, part of Exact Sciences RCV003392593 SCV004120498 likely pathogenic GRHPR-related disorder 2023-09-22 criteria provided, single submitter clinical testing The GRHPR c.139C>T variant is predicted to result in premature protein termination (p.Arg47*). This variant has been reported homozygous in a male individual with primary hyperoxaluria type 2 (Dhondup et al. 2018. PubMed ID: 28681512). Additional protein truncating variants in the GRHPR gene have also been reported to be associated with hyperoxaluria (Williams et al. 2015. PubMed ID: 25629080, Hopp et al. 2015. PubMed ID: 25644115). This variant is reported in 0.0080% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/9-37424897-C-T). Nonsense variants in GRHPR are expected to be pathogenic. This variant is interpreted as likely pathogenic.
Clinical Biochemistry Laboratory, Health Services Laboratory RCV000779582 SCV004174336 pathogenic Primary hyperoxaluria, type II 2023-10-27 criteria provided, single submitter curation ACMG:PVS1 PM2 PP3
Baylor Genetics RCV000779582 SCV004191702 likely pathogenic Primary hyperoxaluria, type II 2024-03-27 criteria provided, single submitter clinical testing
Natera, Inc. RCV000779582 SCV001458445 pathogenic Primary hyperoxaluria, type II 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.